128 related articles for article (PubMed ID: 38750113)
1. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
Br J Cancer; 2024 May; ():. PubMed ID: 38750113
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
Ge H; Ferris RL; Wang JH
Clin Cancer Res; 2023 Feb; 29(3):647-658. PubMed ID: 36315045
[TBL] [Abstract][Full Text] [Related]
5. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
7. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
8. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
[TBL] [Abstract][Full Text] [Related]
10. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
[TBL] [Abstract][Full Text] [Related]
11. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.
Aran A; Lázaro G; Marco V; Molina E; Abancó F; Peg V; Gión M; Garrigós L; Pérez-García J; Cortés J; Martí M
Front Immunol; 2023; 14():1227766. PubMed ID: 37600765
[TBL] [Abstract][Full Text] [Related]
13. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
[TBL] [Abstract][Full Text] [Related]
14. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
15. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
16. TCR repertoire intratumor heterogeneity of CD4
Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z
Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844
[TBL] [Abstract][Full Text] [Related]
17. Single-cell sequencing on CD8
Komuro H; Shinohara S; Fukushima Y; Demachi-Okamura A; Muraoka D; Masago K; Matsui T; Sugita Y; Takahashi Y; Nishida R; Takashima C; Ohki T; Shigematsu Y; Watanabe F; Adachi K; Fukuyama T; Hamana H; Kishi H; Miura D; Tanaka Y; Onoue K; Onoguchi K; Yamashita Y; Stratford R; Clancy T; Yamaguchi R; Kuroda H; Doi K; Iwata H; Matsushita H
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37544663
[TBL] [Abstract][Full Text] [Related]
18. CD4
Lu J; Huang C; He R; Xie R; Li Y; Guo X; Zhang Q; Xu Q
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9007-9016. PubMed ID: 37165118
[TBL] [Abstract][Full Text] [Related]
19. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.
Lee HJ; Kim YA; Sim CK; Heo SH; Song IH; Park HS; Park SY; Bang WS; Park IA; Lee M; Lee JH; Cho YS; Chang S; Jung J; Kim J; Lee SB; Kim SY; Lee MS; Gong G
Oncotarget; 2017 Dec; 8(69):113345-113359. PubMed ID: 29371915
[TBL] [Abstract][Full Text] [Related]
20. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
